

INFORMAȚII PERSONALE

Coriu Daniel

daniel_coriu@yahoo.com

06 Sept 1965



EXPERIENȚA PROFESIONALĂ

Martie 2011 – prezent; Director, Centrul de Hematologie si Transplant Medular, Institutul Clinic Fundeni

Aug 2009- Martie 2011: Director medical Institutul Clinic Fundeni

Feb 2008 – Aug 2009: Sef sectie Hematologie, Centrul de Hematologie si Transplant Medular, Institutul Clinic Fundeni,

2002- Aug 2009: Coordonatorul Laboratorului de Imunochimie si Studiul Proteinelor, Centrul de Hematologie si Transplant Medular, Institutul Clinic Fundeni,

2006- Aug 2009: Coordonatorul Laboratorului de Biologie Moleculara, Centrul de Hematologie si Transplant Medular, Institutul Clinic Fundeni,

LOCUL DE MUNCA

Profesor Universitar de Hematologie, Sef Disciplina Hematologie Fundeni, Director Departament 8, Facultatea de Medicina Generala, Universitatea de Medicina si Farmacie „Carol Davila” – Bucuresti

Medic Primar Hematologie, Sef Centru Centrul de Hematologie si Transplant Medular, Institutul Clinic Fundeni, Bucuresti

Colegiul Medicilor Romania - Presedinte

ACTIVITATE DIDACTICA

Feb 2014 – prezent. Profesor, Catedra de Hematologie Clinica, Facultatea de Medicina Generala, UMF“Carol Davila”, Bucuresti, Romania

Feb 2008 – Feb 2014. Conferentiar, Catedra de Hematologie Clinica, Facultatea de Medicina Generala, UMF“Carol Davila”, Bucuresti, Romania

Feb 2003 – Feb 2008. Sef Lucrari, Catedra de Hematologie Clinica, Facultatea de Medicina Generala, UMF“Carol Davila”, Bucuresti, Romania

Feb 1995- Feb 2003. Asistent Universitar, Catedra de Hematologie Clinica , Facultatea de Medicina Generala, UMF“Carol Davila”, Bucuresti, Romania

EDUCATIE SI FORMARE

Sept 1984-Iunie 1990. M.D.; Universitatea de Medicina si Farmacie “Carol Davila”, Facultatea de Medicina, Bucuresti,

Iulie 1990-Nov 1991. Stagiari - Spitalul Clinic “Sfanta Maria”,Bucuresti

Dec 1991-Dec 1994. Rezidentiat in Hematologie si Hemobiologie, Universitatea de Medicina si Farmacie, Spitalul Clinic Fundeni, Bucuresti,

1995 – Medic Specialist Hematologie

1999 – Medic Primar Hematologie

Aprilie 2000- Martie 2002. International Visiting Scientist prin bursa acordata de American Cancer Society, Facultatea de Medicina, Universitate Tennessee, USA

Iulie 2004- Octombrie 2004. International Visiting Scientist prin bursa acordata de American Cancer Society, Facultatea de Medicina, Universitate Tennessee, USA

May 2006 - Workshop on RQ PCR for monitoring CML patients treated with IMATINIB; Orbassano

March 2004 - Advanced Course in Leukaemia and Lymphoma – organized by ESO and ESMO , A Switzerland

June 1999 - Course on Malignant Lymphoma and Leukemia with Particular Emphasis on Molecular Biology - organized by ESO and ESMO, Ascona – Switzerland

October 1998- 3rd Educational Forum on Leukaemias: State of the Art and Hot ISSUES - organize ESO, Bergamo – Italy

Teza de Doctorat: „AMILOIDOZA PRIMARA : ASPECTE DE DIAGNOSTIC SI TERAPIE , STRUCTURA PROTEINELOR, FIBRILOGENEZA, IDENTIFICAREA REARANJAMENTELOR CLONALE IN SECVENȚA REGIUNII VARIABILE A LANȚURILOR UȘOARE”

Universitatea de Medicina si Farmacie „ Carol Davila ” Bucuresti, 2003.

TEZA DE ABILITARE: “Identificarea mecanismelor moleculare in mielomul multiplu, amiloidoze si leucemii acute “

Universitatea de Medicina si Farmacie „ Carol Davila ” Bucuresti, 2015.

COMPETENTE

Oct 2002: Competenta in Hematologie de Laborator, Ministerul Sanatatii si Familiei, Romania,

Limba(i) maternă(e)

Română

Limba(l) Străină(E) Cunoscută(E)

Engleza

Înțelegere				Vorbire				Scriere	
Ascultare		Citire		Participare la conversație		Discurs oral		Exprimare corecta	
C1	Utilizator experimentat	C1	Utilizator experimentat	C1	Utilizator experimentat	C1	Utilizator experimentat	C1	Utilizator experimentat
X		X		x		x			

Informatii Suplimentare

CONTRACTE / GRANTURI DE CERCETARE:

1. Programul de cercetarea **VIASAN # 217:** “Identificarea si caracterizarea moleculara a mutatiilor din gena care codifica lantul β al globinei la pacientii cu talasemie din Romania”

Perioada: **2003–2005:**

Funcția: **Responsabil Stiintific**

Valoarea proiectului: **1,5 miliarde lei**
 Institutia Coordonatoare: **UMF „Carol Davila”**

2. Program National de Cercetare VIASAN „Mecanisme biologice in leucemiile acute promielocitare . Inducerea diferentierii promielocitelor leucemice prin tratament cu acid-all-transretinoic”. Contract derulat cu Academia de Stiinte Medicale intre 1995-1998.

Functia: membru executant

3. Program National de Cercetare VIASAN „Optimizarea prelucrării materialului biologic destinat aplicării transplantului autolog de maduva osoasa” Contract derulat cu Academia de Stiinte Medicala intre 1998-2001.

Functia: membru executant

4. Programul Cercetare de Excelenta. CEEX # 49

”Screening-ul si diagnosticul prenatal al beta talasemiei – o problema de actualitate in medicina preventiva: Fondarea unui registru national pentru supravegherea bolilor genetice”

Perioada: **2005–2008:**

Functia: **Director de Proiect**

Valoarea proiectului: **10 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

5. Programul Cercetare de Excelenta. CEEX # 74

”Interactiunea micromediei hematopoietic medular cu celula maligna din mielomul multiplu, relatia dintre productia celulara si bolile prin tulburare de conformatie a proteinelor monoclonale”

Perioada: **2006–2008:**

Functia: **Director de Proiect**

Valoarea proiectului: **15 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

6. Proiect CNCSIS 1308: “Studiul expresiei genice prin detectie si cuantificarea transcriptelor BCR-ABL in leucemia mieloida cronica prin RT-PCR si REAL TIME PCR”

Perioada: **2007–2009:**

Functia: **Director de Proiect**

Valoarea proiectului: **2 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

7. Program National de Cercetare – PN II 41-045: „Studiu complex privind caracterizarea determinantilor genetici pentru stabilirea corelatiei genotip- fenotip la pacientii cu talasemie intermediara”

Perioada: **2007–2010:**

Functia: **Director de Proiect din partea Institutului Clinic Fundeni**

Valoarea proiectului: **20 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

8. Program National de Cercetare– PN II 41-087: „Monitorizarea moleculara a oncogenei hibrid BCR-ABL in leucemia mieloida cronica (LMC) prin REAL TIME cantitativ: Fondarea registrului national pentru pacientii cu LMC”

Perioada: **2007–2010:**

Functia: **Director de Proiect**

Valoarea proiectului: **20 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

9. Program National de Cercetare – PN II 099 : “CARACTERIZAREA MOLECULARA A MUTATIILOR IN GENA FACTORULUI V AL COAGULARII IN POPULATIA CU RISC TROMBOFILIC: CORELATII GENOTIP – FENOTIP -TROMBOFILIA- „

Perioada: **2008–2011:**

Functia: **Director de Proiect**

Valoarea proiectului: **20 miliarde lei**

Institutia Coordonatoare: **UMF „Carol Davila”**

10. Program National de Cercetare– PN II 41-032: „Banca de celule stem criopreservate pentru cercetare si transplant autolog”

Perioada: **2007–2010:**

Functia: **Responsabil din partea UMF „Carol Davila”**

Valoarea proiectului: **20 miliarde lei**

Institutia Coordonatoare: **Institutul de Biologie si Patologie Celulara „Nicolae Simionescu”**

11. Programul Cercetare de Excelenta. CEEX # 42

"Noi tinte moleculare si celulare in terapia cu orientare spre pacient a tumorilor maligne. O abordare genomica si proteomica"

Perioada: **2005–2008:**

Functia: **membru executant**

12. Programul Cercetare de Excelenta. CEEX # 48

"Monitorizarea moleculara a prinderii greii de celule stem hematopoietice. Impactul analizei chimerismului in transplantele alogeneice cu regimuri de conditionare mielo si non mieloablative"

Perioada: **2005–2008:**

Functia: **membru executant**

13. Programul Cercetare de Excelenta. CEEX # 75

"Valoarea tipizarii moleculare a profilului HLA pentru optimizarea selectiei donatorilor de allogrefe de celule stem hematopoietice si pentru initierea Registrului National Roman de Donatori"

Perioada: **2006–2008:**

Functia: **membru executant**

14. Programul Cercetare de Excelenta. CEEX # 76

"Optimizarea strategiilor terapeutice in functie de caracteristicile biologice ale celulei maligne in leucemiile acute la copil"

Perioada: **2006–2008:** Functia: **membru executant**

15. Program National de Cercetare– PN II 41-093: "Expresia moleculelor asociate semnalului celular si rearanjarea genica- markeri moleculari clonali identificati in dezvoltarea limfoproliferarilor cu celula B. Constituirea Registrului National de Limfoame Foliculare "

Perioada: 2007–2010:

Functia: membru executant

16. Program National de Cercetare– PN II 41- 007: "Studiu genomic si proteomic si identificarea de noi biomarkeri in boala arteriala oclusa periferica - GENPROTART "

Perioada: 2007–2010:

Functia: membru executant

17. Program National de Cercetare– CNCS PN II –ID-PCE-3-0198: "Studiu calitativ al ecuatiilor diferentiale cu argument deplasat cu aplicatii la modelarea si simularea tratamentului leucemiilor"

Perioada: 2011–2014:

Functia: membru executant

18. Stabilirea Profilului Molecular al Neoplasmelor Mieloproliferative și al Leucemiei Acute Mieloide pentru Designul unor Strategii de Diagnostic Precoce, Prognostic și Tratament (MYELOAL – EDIAPROT), proiect cofinanțat din Fondul European de Dezvoltare Regională prin Programul Operațional COMPETITIVITATE 2014-2020, SMIS: 106774, contract nr 149/26.10.2016; Director de proiect: Prof. Ștefan N. Constantinescu, Institutul de Virusologie „Ștefan S. Nicolau”.

Perioada 2016 – 2020

Functia;

Responsabil de Proiect

Prin finantarea obtinuta din aceste contracte / granturi de cercetare am reusit:

- modernizarea laboratorului de proteomologie prin achizitia si implementarea unor metode si echipamente moderne de lucru in studiul hemoglobinelor (HPLC – High Performance Liquid Chromatography) si studiul proteinelor monoclonale (Free Light Chains Assays). Acest laborator functioneaza deja la capacitate maxima.
- construirea la standarde internationale a unui laborator de Biologie Moleculara Hematologica (suma investita este de aprox. 1 milion EURO). De remarcat ca acest laborator functioneaza din Mai 2007 (acreditat de European LeukemiaNet).

Rezultate importante obtinute si publicate pana in acest moment:

- elucidarea mecanismelor de non-export celular al proteinei monoclonale in mielomul multiplu nesecretant (rezultate publicate ca prim autor in revista BLOOD Aug. 2004 Vol104, Number 3).
- identificarea la nivel de proteina a unui nou tip de amiloid Apolipoproteina A-1 Leu 75 Pro (rezultate publicate ca prim autor in revista Amyloid: J. Protein Folding Disord, Dec. 2003)
- identificarea tipului chimic de amiloid din cartilajul meniscului de la nivelul genunchiului (rezultate publicate in revista Arthritis Rheum. 2006 Nov).
- analiza haplotipului in mutatia appalachian (Ala60) – demonstrarea originii comune cu cea din Irlanda (rezultate publicate in Amyloid: J. Protein Folding Disord, 8, p. 109, 2001)
 - realizarea si implementarea in Romania a diagnosticului molecular in alfa si beta talasemie (rezultate publicate in Journal of Cellular and Molecular Medicine , 8 (2), pp. 232-240, 2004; Haematologica- The Hematology Journal 94, pp. 1209-, 2009; Haematologica- The Hematology Journal, 95, pp. 1752-, 2010)
- realizarea in Romania a primului diagnostic molecular prenatal in beta talasemie (rezultate publicate in Haematologica, The Hematology Journal, Vol 91, supplement no1, June 2006; J Med Life. 2008 Apr-Jun;1(2):138-47
- identificarea la o familie din Romania a unui tip nou de lizozim D67G care induce amiloidoza sistemica ereditara (rezultate publicate in Haematologica / The Hematology journal – Vol 92 (S1), p -448, June 2007)
- identificarea la trei familii din Romania a unui tip nou de transthyretina Glu 54 Gln care induce amiloidoza sistemica ereditara (rezultate prezentate la XIIIth International Symposium on Amyloidosis; Groningen, The Netherlands, May 6-10, 2012)
- realizarea si implementarea in Romania a diagnosticului molecular in leucemii acute (rezultate publicate in Haematologica- The Hematology Journal, 94, pp. 1230-, 2009; Romanian Review of Laboratory Medicine Vol. 20, Nr. 1/4, Martie 2012 ; Romanian Review of Laboratory Medicine Vol. 19, Nr. 4/4, December 2011)
- realizarea si implementarea in Romania a diagnosticului molecular standardizat (Real Time PCR) in leucemia mieloida cronica (rezultate publicate in Haematologica- The Hematology Journal, 94, pp. 1468-, 2009.).
- realizarea si implementarea in Romania a metodelor de identificarea a mutatiilor in domeniu ABL Kinazic in leucemia mieloida cronica (rezultate publicate in Haematologica- The Hematology Journal, 95, pp. 1333-, 2010; Romanian Review of Laboratory Medicine Vol. 19, Nr. 3/4, Septembrie 2011 .
- Identificarea mutațiilor recurente în leucemia acută mieloblastică folosind secvențierea de nouă generație (next generation sequencing). (rezultate publicate in Romanian Review of Laboratory Medicine Vol. 22, Nr. 1/4, 2014 .

**PARTENERIATE ȘTIINȚIFICE
INTERNATIONALE**

- Colaborare în domeniul gamapatiilor monoclonale și amiloidozelor cu **Universitatea Tennessee**, Graduate School of Medicine, Human Immunology and Cancer Program (HICP), USA
- **Framework Package6 (FP6)** : ITHANET ASSOCIATE : Acronym: Ithamet Project Full Title: eInfrastructure for Thalassaemia Research Network No. RI-2004-026539 Funcția: membru în echipa de cercetare. Coordonator din partea UMF "Carol Davila"
- **Framework Package6 (FP6)**: European LeukemiaNet (contract nr. 503216/ 2004). Funcția: membru în echipa de cercetare, Responsabil de implementarea în România a diagnosticului molecular în leucemia mieloidă cronică(**WP4**).
- Proiectul de cercetare **EUTOS for CML (European Treatment and Outcome Study for CML)**. Funcția: Coordonatorul pentru România a Subproiect "Molecular Monitoring".
- **International project - Joint Research Cooperation Programme, Romania - Cyprus**: Phenotype/Genotype Correlation Studies on Haemoglobinopathies; Funcția: Co- Director de Proiect
Instituația coordonatoare: **UMF "Carol Davila"**.
Este un proiect câștigat prin competiție.

STUDII CLINICE

- 1. International Study:** „ A multicentre, randomized Phase III study of Rituximab as Maintenance treatment versus Observation alone in patients with aggressive B-cell lymphoma: NHL-13” , Este un **studiu academic** coordonat de AGMT (Austrian Cooperative Group for Medical Tumor Therapy) Austria.
Funcția: Investigator principal,
- 2. International Study:** „ A Phase IIIb study of Rituximab maintenance therapy in patients with follicular Non- Hodgkin' Lymphoma who have responded to induction therapy.- MAXIMA ” , Este un studiu coordonat de PARAXEL international.
Funcția: Subinvestigator,
- 3. International Study CAMN107EIC01:** A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
Funcția: Investigator principal
- 4. International Study:** A Phase II, a confirmatory multicentre, single - arm study to assess the efficacy, safety, and tolerability of the BITE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B- Precursor acute lymphoblastic leukemia
Funcția: Investigator principal
- 5. International Study CLARION:** „A Randomized, Open-label Phase III study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan and Prednisone in Transplant Ineligible Patient with Newly Diagnosed Multiple Myeloma”
Funcția: Investigator principal
- 6. International Study CAMN107AIC05 (ENESTPath)** - A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID”
Funcția: Investigator principal
- 7. International Study ARROW-** A Randomized, Open-label, Phase III Study in

Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Functia: Investigator principal

2016 -

8. International Study CANDOR- Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Functia: Investigator principal

2017 -

9. International Study A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Functia: Investigator principal

2018 -

10. International Study #2215-CL-0302 "A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission"

Functia: Investigator principal

2018 -

11. International Study ANDROMEDA: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Functia: Investigator principal

2018 -

12. International Study: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

Functia: Investigator principal

2018 –

13. International Study: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis

Functia: Investigator principal

2018 –

14. International Study: colectarea de probe de material biologic în scop științific,

farmacologic și biotehnologic pentru proiectul CPTAC

Functia: Investigator principal

2018 –

14. International Study: A phase 3 Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Functia: Investigator principal

2018 –

ACTIVITATE STIINTIFICA

Web of Science Researcher ID C-3696-2011; H- index 10;
Goggle Academic; H – Index 13

1. Articole in extenso publicate în reviste de specialitate cotate ISI Thomson Reuters (cu factor de impact): 55,
2. Articole publicate în reviste de specialitate indexate in baze de date internationale (BDI, PubMed,): 30,
4. Studii publicate in forma de rezumat in reviste ISI Thomson Reuters (cu factor de impact): 138
5. Studii publicate sub forma de rezumat in revistele unor manifestari stiintifice internationale sau nationale cu ISBN/ISSN:160,

Citari: ISI: 360 ; BDI (Google Scholar): 716, **opt citari in carti internationale** de mare prestigiu *Serum Free Light Chain Analysis*, editia a -III-a, a IV-a, aV-a si respectiv a VI-a. Autor AR Bradwell.

Editor Sef: - Documenta Haematologica – The Journal of Romanian Society of Haematology and Romanian National Society for Blood Transfusion

Membru în colective editoriale (de redactie):

- Romanian Journal of Oncology and Hematology
- The Lancet Oncology, Editia Romana
- Annals of Fundeni – indexata SCOPUS / Elsevier Bibliographic Databases, Amsterdam

Membru in conducerea unor structuri profesional stiintifice internationale:

- Membru **Global Outreach Program Committee (GOPC)** al Societatii Europene de Hematologie, 2020- prezent
- Membru in structura de coordonarea a proiectului international EUTOS, grupul „Molecular Monitoring” si in proiectul European LeukemiaNet grupul de lucru WP 12- Minimal Residual Disease. <http://www.leukemia-net.org>
- Membru in structura de conducere (steering committee) a proiectului European LeukemiaNet / European Science Foundation din 2010; <http://esf-preprod.ameos.net>
- Membru in Medical Advisory Board; Myeloma Patients Europe; <http://www.myelomapatientseurope.org/about-us/medical-advisory-board/>

Membru in conducerea unor structuri profesional stiintifice nationale:

- membru activ in cele mai importante structurile nationale de cercetare: **Membru in Comisia Medicala a Consiliul National al Cercetarii Stiintifice din Invatamantul Superior (CNCSIS) 2008- 2011; Monitor Stiintific (2005- 2008)** in cadrul programului de cercetare **VIASAN** (contract de colaborare 232/ 05 01 2005); **Monitor Stiintific (2005- 2011)** in cadrul programului de cercetare **CEEX** (contract de munca 8 / 01 10 2005); **Expert Evaluator (2006- 2011)** independent in cadrul programului CEEX M1-D01 ((BIOTECH) condus de Centrul National de Management Programe – CNMP ((contract individual de munca nr 111/

05 09 2006); **Consultant (2007- 2009) – Expert** pentru Autoritatea Nationala pentru Cercetare Stiintifica – ANCS (contract 52 / 5 07 2007).

- **membru in comisia de Hematologie a Ministerului Sanatatii: 2013- 2017**
- **vicepresedintele Societatii Romane de Hematologie : 2010 – prezent**
- **Preşedintele Grupului de lucru pentru Gamapatii Monoclonale al Societăţii Române de Hematologie (SRH) din 2011 până în prezent**

Recenzor (reviewer) pentru reviste CNCSIS (cel putin categoria B) sau reviste cotate ISI/BDI:

- Journal of Cellular and Molecular Medicine (ISI)
- American Journal of Therapeutics
- Romanian Review of Laboratory Medicine (ISI)
- Acta Endocrinologica (ISI)
- Polish Archives of Internal Medicine (ISI)
- Documenta Hematologica

Premii/distincţii internaţionale:

- „**International Visiting Scientist**” oferit de catre American Cancer Society si University Tennessee,
- **HELMUT VINAZZER Award for poster presentation** on “Molecular diagnosis of Factor V Leiden, prothrombin G20120A, MTHFR C677T and A1298C mutations in thrombophilic patients” ; 16th International Meeting of Danubian Laegue against Thrombosis and Haemorrhagic Disorders, May 2011, Timisoara,

Premii/distincţii naţionale:

- DIPLOMA Salonului de Carte Universitara pentru lucrarea „Amiloid si Amiloidoza” prezentata la cel de al III –lea Salon National de Carte Universitara desfasurat la Bucuresti in perioada 1-6 octombrie 2007 cu ocazia aniversarii a 150 ani de Invatamant Medical Romanesc.
- PREMIUL DE EXCELENTA , acordat de Academia de Stiinte Medicale din Romania pentru lucrarea stiintifica „Heterogenitatea structurii primare a precursorului proteic al amiloidului: tropismul determinarilor viscerale si al leziunilor tisulare in amiloidoza sistemica” prezentata la simpozionul National VIASAN- CEEX , Sinaia, 2008
- DIPLOMA DE EXCELENTA IN SEMN DE RECUNOSTIINTA, acordat de Asociatia Nationala pentru Protectia Pacientilor, Bucuresti , mai 2012
- PREMIUL TopMedici pentru valoroasa contributie la prestigiul medicinei romanesti, acordat de Gala TopMedici2012.
- Premiul „Excelenta in Sanatate” acordat de Ministerul Sanatatii, 2015

Prezentari invitate in plenul unor manifestari stiintifice internationale:

1. October 2008, Sinaia; The view of Romanian hematologist; A Joint Jose Carreras Leukemia Foundation / EBMT Conference, Assoc. Prof. Dr. D Coriu
2. October 2008, Sinaia : Systemic light chain (AL) amyloidosis: recent discoveries regarding pathogenesis, diagnosis, and treatment; 3rd Balkan Day of Haematology, Assoc. Prof. Dr. Coriu
3. May 2011; Thrombosis and Thrombophilia in pregnancy; Management; D Coriu, 16th International Meeting of Danubian Laegue against Thrombosis and Haemorrhagic Disorders, Timisoara,
4. May 2011; Detection of thrombophilic mutation in patients with obstetric complication; G. Mitroi, C. Ailenei. M. Carstoiu, L. Calin, R. Talmaci, D. Coriu, 16th International Meeting of Danubian Laegue against Thrombosis and Haemorrhagic Disorders, , Timisoara,
5. October 2012; First Line Therapy in Hodgkin’s Lymphoma, D. Coriu, 8th Edition of the Educational Course of the

Lymphoma Working Party on Stem Cell Transplantation in Lymphomas , Bucharest .
 6. May 2013, Bone Marrow Transplantation in Fundeni Clinical Institute; The fourth EBMT training course for paediatricians and pediatric nurses on HSCT in children and adolescents: interactive educational EBMT PDs course, Bucharest.
 7. June 28- 29, 2013; EUTOS population based registry in Romania; D. Coriu, 22 nd International CML- Workshop, Mannheim, Germany
 8. September 29-30, 2017 : Clinical management of patients with multiple myeloma - situation in Romania, D. Coriu; International Myeloma Society, Educational Workshop in Prague, Czech Republic,
 9. November 2-4, 2017; Transthyretin-related hereditary amyloidosis, D. Coriu; 28th. Annual Meeting of Haematology of the Hellenic Society, Athens, Greece.
 10. December, 6- 10 2017, „Amyloidosis - a diagnostic challenge”, D. Coriu; The International Medical Students' Congress, Bucharest, Romania
 11. April 26-27, 2018; Liver involvement in amyloidosis, D. Coriu; 5th UpDate on Hepatology Course, Bucharest
 12. September, 20—21 2018; Transthyretin-related Hereditary Amyloidosis – A Long Journey to Diagnosis ATTR Amyloidosis Academy 2018, Bucharest, Romania
 13. November, 15-16 , 2018; Real-life treatment of MM in Central Eastern Europe; D. Coriu; North East Europe Multiple Myeloma Expert Forum Meeting; Bucharest, Romania
 14. October 26-27, 2018; Multiple myeloma- How to do a correct diagnosis and follow-up- Roundtable; D. Coriu; International Myeloma Society Workshop, Athens, Greece
 15. December, 5- 9 2018, “Adoptive Cell Transfer - A new step in treating haematological malignancies”; D. Coriu; The International Medical Students' Congress, Bucharest, Romania
 16. March. 8- 9 2019, „How I Treat Multiple Myeloma using Transplantation”, Daniel Coriu , Conference- Current and Future Perspectives of Multiple Myeloma, Varsovia, Poland,

COORDONATOR PROGRAME EDUCATIONALE:

- Expert Formator Conf. Dr Daniel Coriu in cadrul proiectului „ Specializare pentru performanta, eficacitate si raspuns in domeniul transplantului de organe ”- S.P.E.R. Coordonator Cursul 2, Modul 4, **Terapii regenerative prin transplant de celule – Transplantul de celule stem de la donator neinruditi**. 2011- 2012
- Coordonator de curs Conf. Dr Daniel Coriu: **“Noutati in abordarea sindromului anemic”**; organizator - Centrul de Excelenta in Medicina de Laborator si Patologie Medcenter, Bucuresti, 20- 21 feb 2014, creditat cu 7 puncte EMC
- Coordonator de curs Conf. Dr Daniel Coriu: „ **Monitorizarea in LMC – de la ghidurile ESMO / ELN la practica clinica in Romania** ”; Organizator Societatea Romana de Hematologie si Universitatea de Medicina „ Carol Davila”, Bucuresti, 13- 15 Iunie 2013; creditat cu 15 puncte EMC
- Coordonator de curs Conf. Dr Daniel Coriu ;”**Monitorizarea moleculară la pacientii cu Leucemie Mieloida Cronica tratati cu ITK - Perspective 2012**” ; Organizator Societatea Romana de Hematologie si Universitatea de Medicina „ Carol Davila”, Bucuresti, 12-13 mai 2012; creditat cu 6 puncte EMC
- Presedintele Conferintei Nationale de Hematologie Clinica si Transfuzionala, Oct 2012, Sinaia
- Coordonator de curs Conf. Dr Daniel Coriu ;”**Monitorizarea moleculară a pacientilor cu LMC tratati cu ITK** ” ; Organizator Societatea Romana de Hematologie si

- Universitatea de Medicina „Carol Davila”, Bucuresti, 28-29 mai 2011; creditat cu 7 puncte EMC
- Coordonator de curs Conf. Dr Daniel Coriu ;” **Curs intensiv de hematologie**” ; Universitatea de Medicina „Carol Davila”, Bucuresti, 17 mai – 1 Iunie 2011; creditat cu 9 puncte EMC
 - Coordonator de curs Prof. Dr Daniel Coriu **“Actualitati in managementul Hemofiliei”** ; Universitatea de Medicina „Carol Davila”, Sinaia, – 10 Oct 2018; creditat cu 3 puncte EMC
 - Presedintele Conferintei Nationale de Hematologie Clinica si Transfuzionala, Oct 2018, Sinaia

Comitete stiintifice pentru organizarea de manifestări științifice naționale

- Ziua Pacientului cu Mielom Multiplu; sept 2010; sept 2011, oct 2012, nov 2013; www.myeloma.ro
 - 6th, 7th, Conference of the Romanian Association of Medical Laboratories with International Participation, June 2011, Piatra Neamt, June 2012, Sinaia, June 2013, Brasov.
 - 2nd Congress of the Romanian Association of Medical Laboratories with International Participation, June 2013, Brasov.
 - Conferinta Nationala de Hematologie Clinica si Transfuzionala, Oct. 2004, oct 2005, Oct 2006, Oct 2007, Oct 2008, Oct 2009, Oct 2010, Oct 2011, Oct 2012, Oct 2013.
- Sesiunea stiintifica Nationala „Grupe de Lucru” : Mai 2011; Mai 2012, Mai 2013

Comitetele științifice ale conferințelor internaționale:

1. 15-16 November 2018; North East Europe Multiple Myeloma Expert Forum Meeting; Bucharest, Romania – Chairman of the Conference
2. 2017 - program committee member of International Myeloma Society Workshop, Prague, Czech Republic, September 29-30, 2017

ASOCIATII PROFESIONALE:

1993-prezent. Societatea Romana de Hematologie (SRH)
1996-prezent. European Society for Medical Oncology (ESMO)
1998-prezent. European Haematology Association (EHA)
2001-prezent. American Society of Clinical Oncology (ASCO)
2006-prezent. International Society of Amyloidosis (ISA)
2020- prezent International Myeloma Society (IMS)

PUBLICATII RELEVANTE

1. Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population.

Jercan A, Ene A, Jurcut R, Draghici M, Badelita S, Dragomir M, Dobrea C, Popescu M, Jordan D, Stoica E, Iacob S, Codita I, Stan C, Coriu D.

Orphanet J Rare Dis. 2020 Jan 30;15(1):34. doi: 10.1186/s13023-020-1309-9.

2. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.

Baccarani M, Iacobucci I, Chiaretti S, Foà R, Balasubramanian P, Paietta E, Foroni L, Jeromin S, Izzo B, Spinelli O, Varma N, Menif S, Terragna C, Seth T, Bidet A, **Coriu D**, Lunghi F, Mayer J, Scappini B, Langabeer S, Maier J, Burt E, Candoni A, Albano F, Luppi M, Zupan I, Lion T, Zadro R, di Raimondo F, Popak B, Rege-Cambrin G, Annunziata M, Ayala A, Salinas-Viedma V, Ines Prado A, Milner B, Galimberti S, Janssen J, Polli V, Comba L, Borsellino B, Annibaldi O, Crugnola M, Passamonti F.

Leukemia. 2019 Oct 8. doi: 10.1038/s41375-019-0591-9.

3. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.

Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, **Coriu D**, Tomuleasa C, Tanase A.

Front Oncol. 2019 Sep 10;9:892. doi:

4. Clinical manifestations in hereditary amyloidosis with the variant Glu54Gln transthyretin.

Jercan A, Badelita S, Draghici M, Stoica E, Iacob S, **Coriu D**.

Amyloid. 2019;26(sup1):31-32. doi: 10.1080/13506129.2019.

5. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, **Coriu D**, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastiris E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/

6. Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.

Mambet C, Babosova O, Defour JP, Leroy E, Necula L, Stanca O, Tatic A, Berbec N, Coriu D, Belickova M, Kralova B, Lanikova L, Vesela J, Pecquet C, Saussoy P, Havelange V, Diaconu CC, Divoky V, Constantinescu SN.

Blood. 2018 Dec 20;132(25):2695-2699.

7. Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries.

Coriu D, Dytfeld D, Niepel D, Spicka I, Markuljak I, Mihaylov G, Ostojic-Kolonic S, Fink L, Toka KS, Björklöf K.

Pol Arch Intern Med. 2018 Sep 28;128(9):500-511. doi: 10.20452/pamw.4305. Epub 2018 Jul 27. Erratum in: Pol Arch Intern Med. 2018 Dec 12;

8. Hypercoagulability and Vascular Disease.

Taher AT, Cappellini MD, Bou-Fakhredin R, **Coriu D**, Musallam KM.

Hematol Oncol Clin North Am. 2018 Apr;32(2):237-245. doi:

9. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, **Coriu D**, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi:

10. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A¹, Rosti G², Cross NC³, Steegmann JL⁴, le Coutre P⁵, Ossenkoppele G⁶, Petrov L⁷, Masszi T⁸, Hellmann A⁹, Griskevicius L¹⁰, Wiktor-Jedrzejczak W¹¹, Rea D¹², **Coriu D**¹³, Brümmendorf TH¹⁴, Porkka¹⁵, Saglio G¹⁶, Gastl G¹⁷, Müller MC¹⁸, Schuld P¹⁹, Di Matteo P²⁰, Pellegrino A²⁰, Dezzani L²⁰, Mahon FX²¹, Baccarani M², Giles FJ²².

Leukemia. 2015 Oct 6. doi: 10.1038/leu.2015.270. [Epub ahead of print]

11. A new assay to identify recurrent mutations in acute myeloid leukemia using next generation sequencing

Coriu D, Jordan D, Jordan C, Tălmaci R, Dragomir M, Coliță A.

Rev Romana Med Lab. 2014;22(1):93-9. DOI:10.2478/rrlm-2014-0003

12. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.

Tatic A, Vasilică M, Coliță A, Vasilache D, Dobrea C, Jordan C, Găman AM, Crișan AM, Coliță D, **Coriu D**.

Rom J Morphol Embryol. 2013;54(4):1177-82

13. The importance of the new prognostic scoring system for evaluating patients with lower-risk myelodysplastic syndrome at diagnosis.

Aurelia Tatic, Cerasela Jordan, Otilia Georgescu, Oana Stanca, Madalina Vasilica, Sorina Badelita, Ana Manuela Crisan, Adriana Colita, Dan Colita, Genica Vulcan, Anca Roxana Lupu, Ionel Iosif, **Daniel Coriu**

Rev Romana Med Lab. 2013;21(3):343-351.

14. New transthyretin variant Glu54Gln associated with familial amyloidosis

D. Coriu, C. Ailenei, R. Talmaci, S. Badelita, C. Dobrea, C.L. Murphy, D. Kestler and A. Solomon

XIIIth International Symposium on Amyloidosis; p 357-360, 2013, sub redactia Bouke P.C. Hazenberg and Johan Bijzet; ISBN 978- 90-821593-0-1

15. Multiplex PCR approach for detection of fusion genes in acute lymphoblastic and myeloid leukemia.

Dumitru Jordan, Rodica Talmaci, Cerasela Jordan, **Daniel Coriu**, Anca Colita, Andrei Colita, et al. Rev Romana Med Lab. 2012;20(1):15-20,

16. Identification of second generation tyrosine kinase inhibitors relevant mutations in a cohort of chronic myeloid leukemia patients treated in a single center in Romania.

Kinga Tatar, Rodica Talmaci, Dumitru Jordan, Maria Damian, Adriana Coliță, Hortensia Ioniță, **Daniel Coriu**. Rev Romana Med Lab. 2011;19(3):279-287;

17. Real-time qPCR for assessment of minimal residual disease in acute myeloid and lymphoid leukemia.

Dumitru Jordan, Rodica Talmaci, Cerasela Jordan, **Daniel Coriu**, Anca Colita, Andrei Colita, et al. Rev Romana Med Lab. 2011;19(4):349-3575.

18. Familial amyloidosis associated with a novel mutation (D67G) in the lysozyme gene

C. Wooliver, **D. Coriu**, C. Murphy, D. Kestler, S. Wang, D. Weiss, G. Becheanu, A. Solomon, Amyloid: J. Protein Folding Disord, 13: 69-69 Suppl. 1 Nov 2006

19. Atherothrombosis in 2 vascular territories in a young woman: importance of thrombophilia testing.

Jurcut R, Florian A, Deleanu D, Arsenescu I, Jurcut C, **Coriu D**, Ginghina C.

Clin Appl Thromb Hemost. 2011 Feb;17(1):108-13. doi: 10.1177/1076029609357740. Epub 2010 May 11.

20. A novel β -globin gene CAP site mutation in association with the 92+1G>A mutation was found in a thalassemia intermedia patient

Dan L. , Talmaci R, Feleki X, **Coriu D**, Vladareanu F , Kleanthous M,

Tecuceanu C, Gavrilă L, Romanian Biotechnological Letters Vol. 16, No. 2, 6042- 6047; 2011;

21. Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I

Solomon, A; Murphy, CL; Kestler; **Coriu, D**; Weiss, DT; Makovitzky,J; Westermark, P

ARTHRITIS AND RHEUMATISM, 54 (11): 3545-3550 NOV 2006;

22. Laparoscopic subtotal splenectomy in hereditary spherocytosis – To preserve the upper or the lower pole of the spleen?

Vasilescu, C; Stanciulea, O; Tudor, S; Stanescu, D; Colita, A; Stoia, R; **Coriu, D**; Colita, A; Arion, C

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 20 (5): 748-752 MAY 2006

23. Scanning of beta-globin gene for identification of beta-thalassemia mutation in Romanian population

Talmaci, R; Traeger-Synodinos, J; Kanavakis, E; **Coriu, D**; Colita, D; Gavrilă, L

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 8 (2): 232-240 APR-JUN 2004;

24. A molecular basis for nonsecretory myeloma

Coriu, D; Weaver, K; Schell, M; Eulitz, M; Murphy, CL; Weiss, DT; Solomon, A
BLOOD, 104 (3): 829-831 AUG 1 2004;

25. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro

Coriu, D; Dispenzieri, A; Stevens, FJ; Murphy, CL; Wang, SC; Weiss, DT; Solomon, A
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 10 (4): 215-223 DEC 2003;

Certificare: Subsemnatul, certific conform cunoștințelor mele, că datele menționate mai sus sunt exacte. Certific de asemenea că nu sunt în conflict de interese referitor la sarcina propusă.

Data: 07 Sept 2021

Semnătura
